Literature DB >> 8878427

Direct preconditioning of cultured chick ventricular myocytes. Novel functions of cardiac adenosine A2a and A3 receptors.

J Strickler1, K A Jacobson, B T Liang.   

Abstract

Preconditioning with brief ischemia before a sustained period of ischemia reduces infarct size in the perfused heart. A cultured chick ventricular myocyte model was developed to investigate the role of adenosine receptor subtypes in cardiac preconditioning. Brief hypoxic exposure, termed preconditioning hypoxia, prior to prolonged hypoxia, protected myocytes against injury induced by the prolonged hypoxia. Activation of the adenosine A1 receptor with CCPA or the A3 receptor with C1-IB-MECA can replace preconditioning hypoxia and simulate preconditioning, with a maximal effect at 100 nM. While activation of the A2a receptor by 1 microM CGS21680 could not mimic preconditioning, its stimulation during preconditioning hypoxia, however, attenuated the protection against hypoxia-induced injury. Blockade of A2a receptors with the selective antagonist CSC (1 microM) during preconditioning hypoxia enhanced the protective effect of preconditioning. Nifedipine, which blocked the A2a receptor-mediated calcium entry, abolished the A2a agonist-induced attenuation of preconditioning. Isoproterenol, forskolin, and BayK 8644, which stimulated calcium entry, also attenuated preconditioning. Nifedipine blocked the increase in calcium uptake by these agents as well as their attenuating effect on preconditioning. The present study provides the first evidence that the adenosine A3 receptor is present on ventricular myocytes and can mediate simulation of preconditioning. The data demonstrate, for the first time, that activation of the A2a receptor antagonizes the preconditioning effect of adenosine, with increased calcium entry during the preconditioning stimuli as a novel mechanism.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8878427      PMCID: PMC507615          DOI: 10.1172/JCI118976

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  35 in total

1.  High-efficiency gene transfer into cardiac myocytes.

Authors:  H Xu; J Miller; B T Liang
Journal:  Nucleic Acids Res       Date:  1992-12-11       Impact factor: 16.971

2.  Adaptation to ischemia during percutaneous transluminal coronary angioplasty. Clinical, hemodynamic, and metabolic features.

Authors:  E Deutsch; M Berger; W G Kussmaul; J W Hirshfeld; H C Herrmann; W K Laskey
Journal:  Circulation       Date:  1990-12       Impact factor: 29.690

3.  A simple and sensitive radioimmunoassay for adenosine.

Authors:  R Yamane; T Nakamura; E Matsuura; H Ishige; M Fujimoto
Journal:  J Immunoassay       Date:  1991

Review 4.  Protective effects of adenosine in myocardial ischemia.

Authors:  S W Ely; R M Berne
Journal:  Circulation       Date:  1992-03       Impact factor: 29.690

5.  Dipyridamole potentiates the myocardial infarct size-limiting effect of ischemic preconditioning.

Authors:  T Miura; T Ogawa; T Iwamoto; K Shimamoto; O Iimura
Journal:  Circulation       Date:  1992-09       Impact factor: 29.690

6.  Improved myocardial ischemic response and enhanced collateral circulation with long repetitive coronary occlusion during angioplasty: a prospective study.

Authors:  A Cribier; L Korsatz; R Koning; P Rath; H Gamra; G Stix; S Merchant; C Chan; B Letac
Journal:  J Am Coll Cardiol       Date:  1992-09       Impact factor: 24.094

7.  Blockade of ischaemic preconditioning in dogs by the novel ATP dependent potassium channel antagonist sodium 5-hydroxydecanoate.

Authors:  J A Auchampach; G J Grover; G J Gross
Journal:  Cardiovasc Res       Date:  1992-11       Impact factor: 10.787

8.  Expression of inducible stress protein 70 in rat heart myogenic cells confers protection against simulated ischemia-induced injury.

Authors:  R Mestril; S H Chi; M R Sayen; K O'Reilly; W H Dillmann
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

9.  Myocardial protection with preconditioning.

Authors:  G C Li; J A Vasquez; K P Gallagher; B R Lucchesi
Journal:  Circulation       Date:  1990-08       Impact factor: 29.690

10.  8-(3-Chlorostyryl)caffeine (CSC) is a selective A2-adenosine antagonist in vitro and in vivo.

Authors:  K A Jacobson; O Nikodijević; W L Padgett; C Gallo-Rodriguez; M Maillard; J W Daly
Journal:  FEBS Lett       Date:  1993-05-24       Impact factor: 4.124

View more
  36 in total

1.  Constitutive activation of A(3) adenosine receptors by site-directed mutagenesis.

Authors:  A Chen; Z G Gao; D Barak; B T Liang; K A Jacobson
Journal:  Biochem Biophys Res Commun       Date:  2001-06-15       Impact factor: 3.575

2.  Targeted deletion of the A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning.

Authors:  Y Guo; R Bolli; W Bao; W J Wu; R G Black; S S Murphree; C A Salvatore; M A Jacobson; J A Auchampach
Journal:  J Mol Cell Cardiol       Date:  2001-04       Impact factor: 5.000

3.  Allosteric modulation of A(3) adenosine receptors by a series of 3-(2-pyridinyl)isoquinoline derivatives.

Authors:  Z G Gao; J E Van Muijlwijk-Koezen; A Chen; C E Müller; A P Ijzerman; K A Jacobson
Journal:  Mol Pharmacol       Date:  2001-11       Impact factor: 4.436

Review 4.  Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering.

Authors:  Kenneth A Jacobson; Athena M Klutz; Dilip K Tosh; Andrei A Ivanov; Delia Preti; Pier Giovanni Baraldi
Journal:  Handb Exp Pharmacol       Date:  2009

Review 5.  Adenosine receptors and reperfusion injury of the heart.

Authors:  John P Headrick; Robert D Lasley
Journal:  Handb Exp Pharmacol       Date:  2009

6.  Protein kinase C-dependent activation of KATP channel enhances adenosine-induced cardioprotection.

Authors:  B T Liang
Journal:  Biochem J       Date:  1998-12-01       Impact factor: 3.857

7.  Overexpression of A(3) adenosine receptors decreases heart rate, preserves energetics, and protects ischemic hearts.

Authors:  Heather R Cross; Elizabeth Murphy; Richard G Black; John Auchampach; Charles Steenbergen
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-06-20       Impact factor: 4.733

Review 8.  Therapeutic receptor targets of ischemic preconditioning.

Authors:  Ryan M Fryer; John A Auchampach; Garrett J Gross
Journal:  Cardiovasc Res       Date:  2002-08-15       Impact factor: 10.787

9.  Adenosine-mediated hypotension in in vivo guinea-pig: receptors involved and role of NO.

Authors:  P Nieri; E Martinotti; V Calderone; M C Breschi
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

10.  Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists.

Authors:  A H Li; S Moro; N Melman; X D Ji; K A Jacobson
Journal:  J Med Chem       Date:  1998-08-13       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.